Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
Bangladesh completes 3-0 clean sweep over Afghanistan in T20 series
- 13 hours ago
Interior Ministry clears Badini border opening
- 14 hours ago
Gold prices hit all-time high
- 14 hours ago
Millat Express escapes major accident near Chichawatni
- 9 hours ago
'He fought too many times': How the loss to Ankalaev forced Pereira to change
- 13 hours ago
Sindh Cabinet waives death certificate fee across province
- 10 hours ago
Israel deports 170 more volunteers detained for attempting to deliver aid to Gaza
- 12 hours ago
Bagram Airbase will not be handed back to US: Taliban
- 11 hours ago
Punjab vs Sindh: Where action speaks louder than promises
- 13 hours ago
Punjab to begin flood relief cheque distribution from October 17
- 9 hours ago
Our guide to every Week 5 NFL game: Matchup previews, predictions, picks and nuggets
- 15 minutes ago
China installs record 295,000 robots as workforce shrinks
- 11 hours ago
